NCT04266288

Effectiveness of Ketamine for Depression and Suicidal Ideation in the Emergency Department

Rapid Antidepressant Response to Ketamine and Impact on Healthcare Utilization After Administration in the Emergency Department

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: MercyOne Des Moines Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to examine the effect of a low-dose ketamine infusion on depression symptoms within the Emergency Department (ED) visit, and healthcare utilization after leaving the ED, when administered in the ED for depression or suicidal ideation.

Detailed description

Patients will be identified based on either a chief complaint of suicidal ideation, suicide attempt, or severe depression, or if the patient indicates during intake assessment that they have thoughts of harming or killing their self. Identified patients will be assessed by the ED provider for inclusion and exclusion criteria. If the patient is a candidate for the trial and gives their informed consent for enrollment, they will be randomized to receive either ketamine or placebo by a computer program that maintains blinding. The patient will be assessed by psychiatry for disposition and treatment plan prior to receiving the study drug, and will be reassessed four hours after the infusion. Thirty days after the patient leaves the hospital (either leaves from the ED or is discharged from inpatient admission), they will be contacted to follow up on their healthcare utilization after discharge.

Conditions

• Depression
• Depression Severe
• Depression Acute
• Depression and Suicide
• Suicidal Ideation

Interventions

Type	Name	Description
DRUG	Ketamine	Active drug
DRUG	Sodium Chloride 0.9%	Placebo

Timeline

• Start date: 2019-10-18
• Primary completion: 2020-05-31
• Completion: 2020-05-31
• First posted: 2020-02-12
• Last updated: 2020-09-01

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study